About: Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.56 (+4.49%)
OVID NASDAQ Ovid Therapeutics Inc
Ovid Therapeutics Inc share price
Atividade de preço de OVID
Último preço
$ 2,560
Variação (24h)
0,11 USD (4,49%)
Volume
2.04M
Volume (média 4 sem.)
-
Abertura
$ 2,45
Variação do dia
$ 2,41 - $ 2,58
Fechamento anterior
$ 2,45
Último negócio
29 Oct, 8:14 pm GMT+0
Atrasado
29 Oct, 8:14 pm GMT+0
OVID price performance
Atrasado
29 Oct, 8:14 pm GMT+0
quote.marketSignals